Related Experiment Video
Updated: Jun 10, 2026

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo
Published on: January 10, 2025
Hypothesis: an erythropoietin honeymoon phase exists
Steven Fishbane1, Nobuyuki Miyawaki, Lynda A Szczech
1Department of Medicine, Winthrop-University Hospital, Mineola, New York 11501, USA. sfishbane@winthrop.org
Abstract:
TREAT was a recently concluded, and well-powered and designed, study of anemia treatment in chronic kidney disease (CKD). Unlike most previous studies of ESA treatment in nondialysis CKD, TREAT was a placebo-controlled trial. The placebo group in TREAT provides a unique long-term view of a conservative approach to anemia management in nondialysis CKD. The course of mean Hgb levels in the placebo group ran counter to expectations, increasing over time. We discuss possible reasons for this, including a new hypothesis that there may be an erythropoietin 'honeymoon phase' similar to that observed in diabetes mellitus. We propose investigation of this phenomenon as it could lead to less expensive and safer approaches to treatment of CKD anemia.
More Related Videos
Related Concept Videos
Erythropoiesis
Erythropoiesis
Factors Affecting Erythropoiesis
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Lifecycle of Erythrocytes
The resident phagocytic macrophages deal with these damaged cells by engulfing them and separating their globin and heme groups.
Ovarian Cycle
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...

